Delaware court refuses to enforce Fresenius/Akorn merger agreement

A judge has ruled that healthcare company Fresenius was entitled to pull out of a planned $4.75 billion takeover of generic drugmaker Akorn, after finding that the target made false representations about the state of its data.


Get unlimited access to all Global Data Review content